Literature DB >> 7496090

Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen.

R L Brent1.   

Abstract

OBJECTIVE: to review the extensive literature pertaining to the reproductive and teratogenic effects of Bendectin and the opinions of the scientific experts for the defense and plaintiff. These data were evaluated with regard to the reproductive risks of Bendectin providing a scientific framework for evaluating the views of the experts in the Bendectin litigation.
DESIGN: the Bendectin literature was primarily obtained from articles cited in Research Alert of the Institute for Science Information. Other articles were obtained from Medline, review articles, and colleagues. An attempt was made to be all-inclusive, citing and reviewing all articles related to each subject being discussed. The literature includes epidemiologic studies, animal studies, in vitro studies, and basic science articles related to the principles of teratology and reproductive toxicology. Review articles, meta analyses, editorials, commentaries, articles in the press, and case reports were also included.
METHODOLOGY: the methodology utilized for the evaluation of Bendectin teratogenicity was presented. It consists of a five-part analysis of epidemiologic studies, secular trend analysis, animal studies, dose-response relationships, and biologic plausibility.
CONCLUSION: the five-part analysis of Bendectin reproductive effects indicates that therapeutic use of Bendectin has no measurable teratogenic effects. Presentations by many of the plantiff's experts failed to meet the scientific standards that should be expected of knowledgeable scientists and contributed to the persistence of Bendectin litigation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496090     DOI: 10.1016/0890-6238(95)00020-b

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  11 in total

1.  The need for greater involvement of regulatory agencies in assessing adverse drug reactions.

Authors:  A D Sniderman
Journal:  CMAJ       Date:  2000-01-25       Impact factor: 8.262

2.  Assessment of antihistamine use in early pregnancy and birth defects.

Authors:  Qian Li; Allen A Mitchell; Martha M Werler; Wai-Ping Yau; Sonia Hernández-Díaz
Journal:  J Allergy Clin Immunol Pract       Date:  2013-09-12

Review 3.  Treatment options for hyperemesis gravidarum.

Authors:  Amy Abramowitz; Emily S Miller; Katherine L Wisner
Journal:  Arch Womens Ment Health       Date:  2017-01-09       Impact factor: 3.633

4.  Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.

Authors:  Marlene Anderka; Allen A Mitchell; Carol Louik; Martha M Werler; Sonia Hernández-Diaz; Sonja A Rasmussen
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-11-19

Review 5.  Evaluation of the reproductive and developmental risks of caffeine.

Authors:  Robert L Brent; Mildred S Christian; Robert M Diener
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2011-03-02

Review 6.  Antihistamines and birth defects: a systematic review of the literature.

Authors:  Suzanne M Gilboa; Elizabeth C Ailes; Ramona P Rai; Jaynia A Anderson; Margaret A Honein
Journal:  Expert Opin Drug Saf       Date:  2014-10-11       Impact factor: 4.250

7.  Use of antihistamine medications during early pregnancy and isolated major malformations.

Authors:  Suzanne M Gilboa; Matthew J Strickland; Andrew F Olshan; Martha M Werler; Adolfo Correa
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-02

8.  Review of NVP and HG and Early Pharmacotherapeutic Intervention.

Authors:  Shannon M Clark; Maged M Costantine; Gary D V Hankins
Journal:  Obstet Gynecol Int       Date:  2011-11-24

Review 9.  Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview.

Authors:  Nina Nuangchamnong; Jennifer Niebyl
Journal:  Int J Womens Health       Date:  2014-04-12

Review 10.  The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy.

Authors:  Svetlana Madjunkova; Caroline Maltepe; Gideon Koren
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.